Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 ...

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...

Pfizer – which first agreed a $4.9 billion takeover deal with Metsera in September – has argued that the rival bid is ...

Eisai has already reached settlement agreements with two other companies seeking to market Lenvima generics in the US – Sun ...

AZ has already made it clear its focus is on investing in the US market – which accounts for 30% of its sales – and started ...

The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...

The DESTINY-Breast11 trial showed in patients with high-risk HER2-positive early breast cancer that the ADC followed by ...

The second batch of Commissioner's national priority vouchers (CNPVs) has been published by the FDA, and includes new GLP-1 ...

According to the White House, Novo Nordisk's semaglutide-based Ozempic for diabetes and Wegovy for obesity will cost $350 per ...

The new data from the OASIS 4 trial of Novo Nordisk's 25 mg oral formulation of semaglutide included an indirect comparison ...

Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the ...

That research led to the FDA granting compassionate use of the doxecitine and doxribtimine treatment in Arturito Estopinan, ...